Literature DB >> 27071350

Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer.

Toru Aoyama1, Takaki Yoshikawa1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27071350     DOI： 10.1038/nrclinonc.2016.53

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Vascular endothelial growth factor signaling pathways: therapeutic perspective.

Authors:  Marcin Kowanetz; Napoleone Ferrara
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

2.  Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Samia H Lopa; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

3.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Authors:  Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

Review 4.  Adjuvant treatments for triple-negative breast cancers.

Authors:  H Joensuu; J Gligorov
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

5.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

Review 6.  Vascular endothelial growth factor and angiogenesis.

Authors:  Ann Hoeben; Bart Landuyt; Martin S Highley; Hans Wildiers; Allan T Van Oosterom; Ernst A De Bruijn
Journal:  Pharmacol Rev       Date:  2004-12       Impact factor: 25.468

7.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Authors:  Jin Li; Shukui Qin; Jianming Xu; Jianping Xiong; Changping Wu; Yuxian Bai; Wei Liu; Jiandong Tong; Yunpeng Liu; Ruihua Xu; Zhehai Wang; Qiong Wang; Xuenong Ouyang; Yan Yang; Yi Ba; Jun Liang; Xiaoyan Lin; Deyun Luo; Rongsheng Zheng; Xin Wang; Guoping Sun; Liwei Wang; Leizhen Zheng; Hong Guo; Jingbo Wu; Nong Xu; Jianwei Yang; Honggang Zhang; Ying Cheng; Ningju Wang; Lei Chen; Zhining Fan; Piaoyang Sun; Hao Yu
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

9.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316
  9 in total
  20 in total

Review 1.  Progress in the treatment of solid tumors with apatinib: a systematic review.

Authors:  Deze Zhao; Helei Hou; Xiaochun Zhang
Journal:  Onco Targets Ther       Date:  2018-07-19       Impact factor: 4.147

Review 2.  Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

3.  Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy.

Authors:  Xu Liu; Qiaoyu Zheng; Qiongfang Yu; Yan Hu; Yanmin Cheng; Zhaozhao Shao; Li Chen; Wenjie Ding; Dian Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

4.  Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202).

Authors:  Xiang Wang; Junyan Yu; Mudan Yang; Likun Liu; Jinghua Gao; Yuchuan Ren; Ruixing Zhang; Diansheng Zhong; Nan Du; Zhanzhao Fu; Junmei Jia; Qingshan Li; Jianfeng Diao; Junping Zhang; Jun Guo; Xiaomei Li; Xiang Song; Yan Zhang; Zhonghe Yu; Liwen Ma; Zaiwen Fan; Zheng Liu; Guozhong Li; Feng Liang; Huaqing Wang; Yunge Gao; Ping Yang; Chunmei Bai; Aimin Zang; Xiubao Ren
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.

Authors:  Ge Zhang; Shuai Gong; Lina Pang; Lixia Hou; Wei He
Journal:  Front Oncol       Date:  2021-05-03       Impact factor: 6.244

Review 6.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

7.  Apatinib has anti-tumor effects and induces autophagy in colon cancer cells.

Authors:  Wu Lu; He Ke; Ding Qianshan; Wang Zhen; Xiang Guoan; Yu Honggang
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

8.  Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.

Authors:  Zhongyu Wang; Yake Huang; Ling Long; Li Zhou; Yan Huang; Lei Gan; Aimin Pu; Sufen Li; Rongkai Xie
Journal:  J Ovarian Res       Date:  2021-07-12       Impact factor: 4.234

9.  Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in esophageal squamous cell carcinoma.

Authors:  Yu-Ming Wang; Xin Xu; Jian Tang; Zhi-Yong Sun; Yu-Jie Fu; Xiao-Jing Zhao; Xiu-Mei Ma; Qing Ye
Journal:  Cell Biosci       Date:  2021-07-06       Impact factor: 7.133

Review 10.  Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.

Authors:  Letizia Procaccio; Vera Damuzzo; Francesca Di Sarra; Alberto Russi; Federica Todino; Vincenzo Dadduzio; Francesca Bergamo; Alessandra Anna Prete; Sara Lonardi; Hans Prenen; Angelo Claudio Palozzo; Fotios Loupakis
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.